ATE405586T1 - Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins - Google Patents

Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins

Info

Publication number
ATE405586T1
ATE405586T1 AT02729263T AT02729263T ATE405586T1 AT E405586 T1 ATE405586 T1 AT E405586T1 AT 02729263 T AT02729263 T AT 02729263T AT 02729263 T AT02729263 T AT 02729263T AT E405586 T1 ATE405586 T1 AT E405586T1
Authority
AT
Austria
Prior art keywords
primates
immune function
regulating immune
foxp3 protein
nucleic acid
Prior art date
Application number
AT02729263T
Other languages
English (en)
Inventor
Roli Khattri
Mary Brunkow
Fred Ramsdell
Original Assignee
Darwin Molecular Corp
Celltech R & D Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Molecular Corp, Celltech R & D Inc filed Critical Darwin Molecular Corp
Application granted granted Critical
Publication of ATE405586T1 publication Critical patent/ATE405586T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/66—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
AT02729263T 2001-05-08 2002-05-08 Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins ATE405586T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28965401P 2001-05-08 2001-05-08
US33340901P 2001-11-26 2001-11-26

Publications (1)

Publication Number Publication Date
ATE405586T1 true ATE405586T1 (de) 2008-09-15

Family

ID=26965773

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729263T ATE405586T1 (de) 2001-05-08 2002-05-08 Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins

Country Status (7)

Country Link
US (2) US7507542B2 (de)
EP (2) EP1967525B1 (de)
JP (2) JP4353701B2 (de)
AT (1) ATE405586T1 (de)
CA (1) CA2446112C (de)
DE (1) DE60228477D1 (de)
WO (1) WO2002090600A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2339409A1 (en) * 1998-08-11 2000-02-24 Darwin Discovery Ltd. Identification of the gene causing the mouse scurfy phenotype and its human ortholog
US7507542B2 (en) * 2001-05-08 2009-03-24 Ucb Sa Method for regulating immune function using the FOXP3 protein
CA2575604A1 (en) 2004-07-30 2006-02-02 Oregon Health And Science University Methods for detecting and treating autoimmune disorders
WO2006044864A2 (en) * 2004-10-19 2006-04-27 Duke University Vaccine adjuvant
US20060165687A1 (en) * 2004-10-19 2006-07-27 Duke University Vaccine adjuvant
US20100061984A1 (en) * 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
ATE508207T1 (de) 2006-02-28 2011-05-15 Charite Universitaetsmedizin Nachweis und qualitätskontrolle von regulator-t- zellen mittels dna-methylierungsanalyse des foxp3-gens
WO2007113301A1 (en) * 2006-04-03 2007-10-11 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
WO2008002107A1 (en) * 2006-06-30 2008-01-03 Forhumantech Co., Ltd. Pharmaceutical composition for treating autoimmune, allergic and inflammatory diseases and delivery method thereof
GB0614536D0 (en) * 2006-07-21 2006-08-30 Metcalfe Susan M Methods of controlling cellular response to LIF
WO2008066784A2 (en) * 2006-11-27 2008-06-05 Ludwig Institute For Cancer Research Expression of foxp3 by cancer cells
TWI441648B (zh) * 2007-01-03 2014-06-21 Oncotherapy Science Inc Foxp3胜肽疫苗
US20100310635A1 (en) * 2007-04-25 2010-12-09 Engin Ozkaynak Compositions and Methods for Regulating T-Cell Activity
US8158596B2 (en) 2007-05-11 2012-04-17 The Regents Of The University Of Michigan Materials and methods for FOXP3 tumor suppression
GB0718160D0 (en) * 2007-09-18 2007-10-24 Medical Res Council Methods
ES2328776B1 (es) * 2007-11-19 2010-07-06 Proyecto De Biomedicina Cima S.L. Peptidos con capacidad para unirse a escurfina y aplicaciones.
WO2010101870A1 (en) 2009-03-03 2010-09-10 St. Jude Children's Research Hospital Compositions and methods for generating interleukin-35-induced regulatory t cells
US9228171B2 (en) 2010-02-05 2016-01-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulatory B cells (tBREGS) and their use
WO2013151490A1 (en) * 2012-04-02 2013-10-10 John Andersson Methods and compounds for treating diseases
JP2015523854A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Smn遺伝子ファミリー発現を調節するための組成物及び方法
CN104583402A (zh) 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
CN104540946A (zh) 2012-05-16 2015-04-22 Rana医疗有限公司 用于调节utrn表达的组合物和方法
EA201492120A1 (ru) 2012-05-16 2015-10-30 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии atp2a2
WO2014180943A1 (en) * 2013-05-08 2014-11-13 Vib Vzw Mcl-1 as critical regulator of foxp3+ regulatory t cell survival, and use thereof to treat severe immune disorders
KR20160027968A (ko) * 2013-06-07 2016-03-10 라나 테라퓨틱스, 인크. Foxp3 발현을 조절하기 위한 조성물 및 방법
CA3042179A1 (en) 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
WO2019040655A1 (en) 2017-08-22 2019-02-28 The Regents Of The University Of California LENTIVIRAL VECTORS EXPRESSING FOXP3 IN HEMATOPOIETIC STEM CELLS TO TREAT IMMUNITY DEFICIENCIES AND AUTOIMMUNE DISEASES
EP3758736B1 (de) 2018-03-02 2024-05-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Il-34 zur anwendung in einem verfahren zur behandlung von retinaler entzündung und neurodegeneration
US12227756B2 (en) 2018-04-18 2025-02-18 Ucl Business Ltd Engineered regulatory T cell
SG11202007878UA (en) 2018-04-27 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Expression of foxp3 in edited cd34+ cells
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
US11091524B1 (en) 2020-04-22 2021-08-17 Houston Gene Therapeutics Llc Compositions for treatment of vascular disease

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018884A (en) 1975-06-26 1977-04-19 Hoffmann-La Roche Inc. Fluorogenic materials and labeling techniques
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4359535A (en) 1979-10-01 1982-11-16 George Pieczenik Autonomously replicating DNA containing inserted DNA sequences
US4528266A (en) 1979-10-01 1985-07-09 George Pieczenik Method of inserting unique DNA sequences into DNA vectors
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4786600A (en) 1984-05-25 1988-11-22 The Trustees Of Columbia University In The City Of New York Autocatalytic replication of recombinant RNA
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US5087571A (en) 1984-06-22 1992-02-11 President And Fellows Of Harvard College Method for providing a cell culture from a transgenic non-human mammal
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4736888A (en) 1985-06-26 1988-04-12 Fasnacht Kenneth P Row crop band sprayer
US4744981A (en) 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US4876187A (en) 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
US5011769A (en) 1985-12-05 1991-04-30 Meiogenics U.S. Limited Partnership Methods for detecting nucleic acid sequences
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
EP0289121B1 (de) 1987-05-01 1995-12-27 Stratagene Mutagenesetest durch Verwendung von nicht menschlichen Lebewesen, die Test-DNS-Sequenzen enthalten
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
EP0329184A3 (de) 1988-02-19 1990-05-23 Neorx Corporation Antimere und antimere Konjugation
US4988496A (en) 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5221778A (en) 1988-08-24 1993-06-22 Yale University Multiplex gene regulation
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
EP0832980B1 (de) 1989-01-23 2002-06-19 Chiron Corporation Rekombinanttherapien für Infektionen und hyperproliferative Störungen
US5175383A (en) 1989-02-17 1992-12-29 President And Fellows Of Harvard College Animal model for benign prostatic disease
GB8914543D0 (en) 1989-06-23 1989-08-09 Parker David Chemical compounds
EP1001032A3 (de) 1989-08-18 2005-02-23 Chiron Corporation Rekombinante Retroviren um Vektorkonstruktionen an Zielzellen zu liefern
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5359051A (en) 1990-01-11 1994-10-25 Isis Pharmaceuticals Compounds useful in the synthesis of nucleic acids capable of cleaning RNA
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
JPH06507782A (ja) 1990-06-15 1994-09-08 サイオス ノバ インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
DE4028955A1 (de) * 1990-09-12 1992-03-19 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen den interleukin 2-rezeptor
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0650370A4 (de) 1992-06-08 1995-11-22 Univ California Auf spezifische gewebe abzielende verfahren und zusammensetzungen.
EP0644946A4 (de) 1992-06-10 1997-03-12 Us Health Gegen die inaktivierung durch menschliches serum resistente vektorpartikel.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
IL108719A0 (en) 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
EP0708751A1 (de) 1993-07-16 1996-05-01 The Regents Of The University Of California Synthese einer kombinatorischen matrix von organischen verbindungen durch die verwendung einer kombinatorischen mehrkomponenten matrix synthese
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
EP0712493A4 (de) 1993-08-03 1997-01-15 Sphinx Pharma Corp Verfahren zur herstellung und auswahl pharmazeutisch nützlicher nicht-peptid verbindungen aus einer universellen sammlung unterschiedlicher strukturen
US5624803A (en) 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
EP0733103B1 (de) 1993-11-09 2004-03-03 Targeted Genetics Corporation Die erzielung hoher titer des rekombinanten aav-vektors
EP0733213A1 (de) 1993-12-09 1996-09-25 Novartis AG Verfahren zur herstellung von bibliotheken aus kombinatorischen verbindungen
ATE160223T1 (de) 1993-12-15 1997-11-15 Combichem Inc Kombinatorische bibliotheken und verfahren zu ihrer verwendung
EP0734398B1 (de) 1993-12-15 2002-02-27 Smithkline Beecham Corporation Verbindungen und verfahren
DE69530683T2 (de) 1994-03-11 2004-03-25 Pharmacopeia, Inc. Sulfonamid derivate und deren verwendung
JPH10500112A (ja) 1994-05-06 1998-01-06 ファーマコピーア,インコーポレイテッド 組合せ ジヒドロベンゾピラン ライブラリー
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5610015A (en) 1995-03-23 1997-03-11 Wisconsin Alumni Research Foundation System to detect protein-RNA interactions
US5700289A (en) * 1995-10-20 1997-12-23 North Shore University Hospital Research Corporation Tissue-engineered bone repair using cultured periosteal cells
US5854279A (en) * 1996-06-04 1998-12-29 Eisai Co., Ltd Therapeutic agent for dermatosis
AU738102B2 (en) 1997-07-02 2001-09-06 Washington State University Research Foundation Methods for the isolation of proteinase inhibitor proteins from potato tubers
GB9721909D0 (en) 1997-10-17 1997-12-17 Cantab Pharma Res Gene delivery vectors and their uses
JP2001520047A (ja) 1997-10-21 2001-10-30 ターゲテッド ジェネティックス コーポレイション 組換えaavベクターと共に使用するための転写活性化された逆方向末端反復(itr)
JP2001520051A (ja) 1997-10-21 2001-10-30 ターゲテッド ジェネティックス コーポレイション 組換えaavベクターの産生のための増幅可能アデノ随伴ウイルス(aav)パッケージングカセット
CA2339409A1 (en) * 1998-08-11 2000-02-24 Darwin Discovery Ltd. Identification of the gene causing the mouse scurfy phenotype and its human ortholog
WO2002016656A2 (en) * 2000-08-21 2002-02-28 Celltech R & D, Inc. Methods for detecting mutations in the human scurfy/foxp3 gene
US7507542B2 (en) * 2001-05-08 2009-03-24 Ucb Sa Method for regulating immune function using the FOXP3 protein
US6878523B2 (en) * 2002-05-08 2005-04-12 Gentel Bio Surfaces, Inc. Molecular interaction assays on a solid surface

Also Published As

Publication number Publication date
EP1967525A3 (de) 2009-03-11
US20090169543A1 (en) 2009-07-02
JP2004532036A (ja) 2004-10-21
WO2002090600A2 (en) 2002-11-14
DE60228477D1 (de) 2008-10-02
EP1446500A4 (de) 2006-01-11
US20030170648A1 (en) 2003-09-11
WO2002090600A3 (en) 2004-06-10
JP4353701B2 (ja) 2009-10-28
EP1967525A2 (de) 2008-09-10
US7507542B2 (en) 2009-03-24
EP1967525B1 (de) 2012-11-14
EP1446500A2 (de) 2004-08-18
JP2008220379A (ja) 2008-09-25
CA2446112A1 (en) 2002-11-14
CA2446112C (en) 2011-04-26
EP1446500B1 (de) 2008-08-20

Similar Documents

Publication Publication Date Title
DE60228477D1 (de) Verfahren zur regulierung der immunfunktion in primaten unter verwendung des foxp3-proteins
ATE421994T1 (de) Genexpressionsmethode
EP1564550A3 (de) Verfahren zur Analyse von Proteinen durch isoelektrische Fokussierung einer Lösung
ATE420061T1 (de) 13c,15n,2h markierte proteine zur nmr strukturbestimmung und deren herstellung
DE69433690D1 (de) Chimere proteine, welche borrelia polypeptide beinhalten, verwendungen dafür
EP1517144A3 (de) Verfahren zur Identifizierung eines Antikörpers, der einen humanen Vanilloid Rezeptor bindet und dessen Aktivität moduliert
WO2004019893A3 (en) Modulators of angiogenesis
WO2000009693A3 (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
EP2266628A3 (de) Methode zur Bestimmung der Anfälligkeit für Knochenmetastasen über die Expression von EPhA2
DE602004032345D1 (de) Reagenzien und verfahren zur bildung von disulfid-bindungen und glykosylierung von proteinen
ATE489478T1 (de) Nukleinsäuren, polypeptide und verfahren zur apoptosemodulation
ATE474922T1 (de) Fluoreszenzproteine aus copepoda-spezies und verfahren zur verwendung davon
WO2004074448A3 (en) mTOR KINASE-ASSOCIATED PROTEINS
EP1847611A3 (de) Rhamnose-induzierbares Expressionssystem
ATE161049T1 (de) Verfahren und nukleinsäuresequenzen zur expression des zellulose-synthase-operons
WO2001092493A3 (en) 21956 and 25856, human aminopeptidases and uses thereof
WO2004018636A3 (en) Methods for modulating transcriptional activation using mint proteins
EP1181351A4 (de) Verfahren zur aufreinigung heterologer proteine
WO2001083752A3 (en) 23949 and 32391, human ion channels and uses thereof
DE60011785D1 (de) Verfahren zur herstellung von proteinen in wirtszellen unter verwendung von chaperoninen
DE69426018D1 (de) Ein mutiertes crp-protein und verfahren und mittel zu dessen herstellung und verwendung
ATE419350T1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc- 2
ATE556135T1 (de) Neues protein
AU2002234132A1 (en) 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
WO2001066745A3 (en) Presenilin/crk binding polypeptides (pcbp) and methods of use thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties